SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR [R44])

Post Date

May 14th 2008

Application Due Date

February 27th 2009

Funding Opportunity Number

RFA-CA-08-021

CFDA Number(s)

93.394
93.395

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

Small Businesses

Funding

• Estimated Total Funding:

  $10000000

• Award Range:

  $None - $None

Grant Description

Purpose. This Funding Opportunity Announcement (FOA), launched as a pilot initiative at the National Institutes of Health (NIH) by the National Cancer Institute (NCI), solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional NIH funding to support the next stage of development for previously-funded NIH SBIR Phase II projects applicable to cancer therapies and cancer imaging technologies.ÊThe purpose of this FOA is to address the funding gap known as the Valley of Death between the end of the SBIR Phase II award and the commercialization stage.ÊThis FOA is also designed to promote partnerships between NIH s SBIR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital intensive steps that are required to commercialize new products/technologies emerging from NIH-funded SBIR Phase II projects.ÊApplicants responding to this FOA must provide a specific commercialization plan that includes details on any independent third-party investor funding that has already been secured or is anticipated.ÊIt is expected that the level of this independent third-party funding will equal or exceed the NCI funds being requested throughout the Phase II Bridge Award project period.ÊNCI support is thus intended to benefit cancer patients by accelerating the development of new cancer therapies (including anticancer agents and oncological therapeutic devices) and imaging devices/technologies toward commercialization.ÊOnly applications proposing projects in these areas will be considered responsive.ÊProposed projects may address preclinical and/or clinical stages of technology development.ÊClinical trials may be proposed as needed but are not required.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-021.html